Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial

Author(s): Kallirroi I. Kalantzi, Ioannis V. Ntalas, Vasileios G. Chantzichristos, Maria E. Tsoumani, Dimitrios Adamopoulos, Christos Asimakopoulos, Adamantios Bourdakis, Petros Darmanis, Alexandra Dimitriadou, Stefanos Gkiokas, Konstantinos Ipeirotis, Kyriaki Kitikidou, Ioannis Klonaris, Aglaia Kostaki, Dimitrios Logothetis, Konstantinos Mainas, Theodoros Mais, Athanasios Maragiannis, Konstantina Martiadou, Konstantinos Mavronasos, Ioannis Michelongonas, Dimitrios Mitropoulos, Georgios Papadimitriou, Achilleas Papadopoulos, Miltiadis Papaioakeim, Kosmas Sofillas, Sotiria Stabola, Emmanouil Stefanakis, Dimitrios Stergiou, Maria Thoma, Alexandros Zenetos, Stergios Zisekas, John A. Goudevenos, Demosthenes B. Panagiotakos, Alexandros D. Tselepis*

Journal Name: Current Vascular Pharmacology

Volume 17 , Issue 6 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events.

Objective: We performed a randomised, multicentre, phase 4 clinical trial to compare the clinical efficacy and safety of triflusal versus aspirin, administered for 12 months in patients eligible to receive a cyclooxygenase-1 (COX-1) inhibitor.

Methods: Patients with stable coronary artery disease or with a history of non-cardioembolic ischaemic stroke were randomly assigned to receive either triflusal 300 mg twice or 600 mg once daily or aspirin 100 mg once daily for 12 months. The primary efficacy endpoint was the composite of: (a) ΜΙ, (b) stroke (ischaemic or haemorrhagic), or, (c) death from vascular causes for the entire follow-up period. The primary safety endpoints were the rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.

Results: At 12-month follow-up, an equivalent result was revealed between the triflusal (n=559) and aspirin (n=560) in primary efficacy endpoint. Specifically, the combined efficacy outcome rate (i.e. MI, stroke or death from vascular causes) difference was equal to -1.3% (95% confidence interval -1.1 to 3.5) and lied within the a-priori defined equivalence interval (p<0.001). Regarding the primary safety endpoints, patients on triflusal treatment were 50% less likely to develop bleeding events according to the BARC criteria, and especially any clinically overt sign of haemorrhage that requires diagnostic studies, hospitalisation or special treatment (BARC type 2).

Conclusion: The efficacy of triflusal in the secondary prevention of vascular events is similar to aspirin when administered for 12 months. Importantly, triflusal significantly reduced the incidence of ΜΙ and showed a better safety profile compared with aspirin.

(ASpirin versus Triflusal for Event Reduction In Atherothrombosis Secondary prevention, ASTERIAS trial; Clinical Trials.gov Identifier: NCT02616497).

Keywords: Aspirin, bleeding, coronary artery disease, myocardial infarction, stroke, triflusal.

[1]
Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: 89-119.
[2]
Antithrombotic Trialists’ Collaboration.Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
[3]
Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 9: 154-69.
[4]
Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008; 336: 195-8.
[5]
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9.
[6]
Di Minno G. Aspirin resistance and platelet turnover: A 25-year old issue. Nutr Metab Cardiovasc Dis 2011; 21: 542-5.
[7]
Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75: 1-18.
[8]
Cruz-Fernández JM, López-Bescós L, García-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000; 21: 457-65.
[9]
Matías-Guiu J, Álvarez-Sabín J, Codina A. Comparative study of the effect of acetylsalicylic acid in low doses and triflusal in the prevention of cardiovascular events in young adults with ischemic cerebrovascular disease. Rev Neurol 1997; 25: 1669-72.
[10]
Matías-Guiu J, Ferro JM, Alvarez-Sabin J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: The TACIP study: A randomized, double-blind, multicenter trial. Stroke 2003; 34: 840-8.
[11]
Culebras A, Rotta-Escalante R, Vila J, et al. TAPIRSS investigators.Triflusal vs. aspirin for prevention of cerebral infarction: A randomized stroke study. Neurology 2004; 62(7): 1073-80.
[12]
Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; 3CD004296
[13]
Murdoch D, Plosker GL. Triflusal: A review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drugs 2006; 66: 671-92.
[14]
Antonijoan RM, Gich I, Azaro A, et al. Gastrointestinal safety of triflusal solution in healthy volunteers: A proof of concept endoscopic study. Eur J Clin Pharmacol 2011; 67: 663-9.
[15]
Latib A, Ielasi A, Ferri L, et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. Int J Cardiol 2013; 165: 444-7.
[16]
Ibáñez L, Vidal X, Vendrell L, Moretti U, Laporte JR. Spanish- Italian Collaborative Group for the Epidemiology of Gastrointestinal BleedingUpper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006; 23: 235-42.
[17]
Lanas A, Serrano P, Bajador E, Fuentes J, Sáinz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2003; 15: 173-8.
[18]
McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-38.
[19]
Fuertes Ferre G, Laita Monreal S, Ortas Nadal MDR, Sánchez Insa E, Sánchez Rubio-Lezcano J, Galache Osuna JG. Triflusal in patients with aspirin hypersensitivity treated with coronary stent implantation. Rev Esp Cardiol 2018; 71: 584-5.
[20]
Tsoumani ME, Kalantzi KI, Goudevenos IA, Tselepis AD. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions. Curr Vasc Pharmacol 2012; 10: 539-49.
[21]
Atalar E, Aytemir K, Haznedaroğlu I, et al. Platelet and leukocyte deactivation after intracoronary stent placement in patients receiving combined antiplatelet therapy. Clin Appl Thromb Hemost 2001; 7: 116-21.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 6
Year: 2019
Page: [635 - 643]
Pages: 9
DOI: 10.2174/1570161116666180605090520
Price: $65

Article Metrics

PDF: 45
HTML: 3